Published in J Oncol on January 13, 2010
Regulation of macroautophagy in ovarian cancer cells in vitro and in vivo by controlling glucose regulatory protein 78 and AMPK. Oncotarget (2012) 1.08
Blocking epidermal growth factor receptor activation by 3,3'-diindolylmethane suppresses ovarian tumor growth in vitro and in vivo. J Pharmacol Exp Ther (2011) 0.99
Identification of the IGF1/PI3K/NF κB/ERK gene signalling networks associated with chemotherapy resistance and treatment response in high-grade serous epithelial ovarian cancer. BMC Cancer (2013) 0.93
EGFR/HER-targeted therapeutics in ovarian cancer. Future Med Chem (2012) 0.90
High incidence of ErbB3, ErbB4, and MET expression in ovarian cancer. Int J Gynecol Pathol (2014) 0.88
Inhibition of EGFR-AKT axis results in the suppression of ovarian tumors in vitro and in preclinical mouse model. PLoS One (2012) 0.88
Utility of vascular endothelial growth factor inhibitors in the treatment of ovarian cancer: from concept to application. J Oncol (2011) 0.79
Influence of CYP3A4 genotypes in the outcome of serous ovarian cancer patients treated with first-line chemotherapy: implication of a CYP3A4 activity profile. Int J Clin Exp Med (2013) 0.77
Ovarian cancer and DNA repair: DNA ligase IV as a potential key. World J Clin Oncol (2013) 0.76
Pattern of triple negative epithelial ovarian cancer in indigenous African women. F1000Res (2016) 0.75
Cancer statistics, 2008. CA Cancer J Clin (2008) 86.74
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
Tumor angiogenesis: therapeutic implications. N Engl J Med (1971) 35.36
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature (2005) 26.32
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med (2009) 24.75
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature (2005) 19.13
The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer (2005) 8.99
Resistance to therapy caused by intragenic deletion in BRCA2. Nature (2008) 5.85
Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol (2007) 5.81
Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol (2007) 5.13
Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol (2002) 4.25
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst (2007) 3.95
Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol (2008) 3.71
A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol (2008) 3.59
Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer (2009) 3.46
Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res (2005) 2.72
Targeted therapy for cancer using PARP inhibitors. Curr Opin Pharmacol (2008) 2.40
Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin Cancer Res (2005) 2.22
Epidemiology of ovarian cancer. Methods Mol Biol (2009) 2.18
Novel agents on the horizon for cancer therapy. CA Cancer J Clin (2009) 2.11
Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res (2003) 2.06
Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study. Int J Gynecol Cancer (2005) 1.83
Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer. Gynecol Oncol (2006) 1.79
Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol (2006) 1.65
Raf: a strategic target for therapeutic development against cancer. J Clin Oncol (2005) 1.63
A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer. Cancer (2007) 1.36
HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group. Ann Oncol (2004) 1.31
Experience with bevacizumab in the management of epithelial ovarian cancer. J Clin Oncol (2007) 1.29
Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol (2008) 1.29
Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer (2002) 1.25
A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies. Gynecol Oncol (2006) 1.22
Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening. Gynecol Oncol (2007) 1.14
Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study. Gynecol Oncol (2008) 1.14
Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. Gynecol Oncol (2009) 1.14
A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer. Int J Gynecol Cancer (2007) 1.13
New therapies for ovarian cancer: cytotoxics and molecularly targeted agents. Crit Rev Oncol Hematol (2008) 1.08
Anti-epidermal growth factor receptor drugs in cancer therapy. Expert Opin Investig Drugs (2002) 1.08
Efficient deletion of normal Brca2-deficient intestinal epithelium by poly(ADP-ribose) polymerase inhibition models potential prophylactic therapy. Cancer Res (2005) 1.08
Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer. Gynecol Oncol (2005) 1.05
A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer. Gynecol Oncol (2008) 1.05
Strand breaks arising from the repair of the 5-bromodeoxyuridine-substituted template and methyl methanesulphonate-induced lesions can explain the formation of sister chromatid exchanges. Chromosoma (1985) 1.04
The emerging role of epidermal growth factor receptor inhibitors in ovarian cancer. Int J Gynecol Cancer (2007) 1.03
Sporadic epithelial ovarian cancer: clinical relevance of BRCA1 inhibition in the DNA damage and repair pathway. J Clin Oncol (2008) 1.02
Overexpression of c-erbB-2 in epithelial ovarian cancer. Prognostic value and relationship with response to chemotherapy. Cancer (1995) 0.98
Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy--a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6). Gynecol Oncol (2006) 0.94
A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers. Br J Cancer (2008) 0.87
A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer. Int J Gynecol Cancer (2007) 0.83
The promise and perils of 'targeted therapy' of advanced ovarian cancer. Oncology (2008) 0.78
Robotically assisted vs laparoscopic hysterectomy among women with benign gynecologic disease. JAMA (2013) 4.67
Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol (2010) 3.33
Evaluation of third-degree and fourth-degree laceration rates as quality indicators. Obstet Gynecol (2015) 2.64
Comparative effectiveness of robotic versus laparoscopic hysterectomy for endometrial cancer. J Clin Oncol (2012) 2.59
Identification of copy number gain and overexpressed genes on chromosome arm 20q by an integrative genomic approach in cervical cancer: potential role in progression. Genes Chromosomes Cancer (2008) 2.29
Resource utilization for ovarian cancer patients at the end of life: how much is too much? Gynecol Oncol (2005) 2.26
Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol (2013) 2.24
Uptake and economic impact of first-cycle colony-stimulating factor use during adjuvant treatment of breast cancer. J Clin Oncol (2012) 2.21
Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol (2007) 2.20
Lymphadenectomy influences the utilization of adjuvant radiation treatment for endometrial cancer. Am J Obstet Gynecol (2011) 2.19
Racial disparities for uterine corpus tumors: changes in clinical characteristics and treatment over time. Cancer (2009) 2.15
Surgical-pathological predictors of disease-free survival and risk groupings for IB2 cervical cancer: do the traditional models still apply? Gynecol Oncol (2004) 2.08
Nationwide trends in the performance of inpatient hysterectomy in the United States. Obstet Gynecol (2013) 2.05
Prognostic significance of adenocarcinoma histology in women with cervical cancer. Gynecol Oncol (2012) 1.98
Comparative performance of the 2009 international Federation of gynecology and obstetrics' staging system for uterine corpus cancer. Obstet Gynecol (2010) 1.98
Trends and Predictors of Cerclage Use in the United States From 2005 to 2012. Obstet Gynecol (2015) 1.96
Predictors of massive blood loss in women with placenta accreta. Am J Obstet Gynecol (2011) 1.86
Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers. Proc Natl Acad Sci U S A (2003) 1.83
Primary therapy for early-stage cervical cancer: radical hysterectomy vs radiation. Am J Obstet Gynecol (2009) 1.75
Trends in hospital volume and patterns of referral for women with gynecologic cancers. Obstet Gynecol (2013) 1.72
Use of complementary and alternative medicine among women with gynecologic cancers. Gynecol Oncol (2002) 1.72
Cervical carcinoma in the elderly: an analysis of patterns of care and outcome. Cancer (2005) 1.68
Defining the limits of radical cytoreductive surgery for ovarian cancer. Gynecol Oncol (2011) 1.66
Management of symptomatic ascites in recurrent ovarian cancer patients using an intra-abdominal semi-permanent catheter. Am J Hosp Palliat Care (2002) 1.65
Effect of surgical volume on outcomes for laparoscopic hysterectomy for benign indications. Obstet Gynecol (2012) 1.58
Incidence and predictors of bowel obstruction in elderly patients with stage IV colon cancer: a population-based cohort study. JAMA Surg (2013) 1.57
Penetrance and expressivity of MSH6 germline mutations in seven kindreds not ascertained by family history. Am J Hum Genet (2004) 1.57
Regionalization of care for obstetric hemorrhage and its effect on maternal mortality. Obstet Gynecol (2010) 1.56
The effect of surgeon volume on outcomes and resource use for vaginal hysterectomy. Obstet Gynecol (2010) 1.56
Scientific evidence underlying the American College of Obstetricians and Gynecologists' practice bulletins. Obstet Gynecol (2011) 1.55
Trends in surgical mesh use for pelvic organ prolapse from 2000 to 2010. Obstet Gynecol (2012) 1.55
A prospective study evaluating the clinical relevance of a chemoresponse assay for treatment of patients with persistent or recurrent ovarian cancer. Gynecol Oncol (2013) 1.54
Contemporary management of endometrial cancer. Lancet (2012) 1.51
Comparative effectiveness research in oncology methodology: observational data. J Clin Oncol (2012) 1.49
Variation in ovarian conservation in women undergoing hysterectomy for benign indications. Obstet Gynecol (2013) 1.46
Postpartum sterilization: small incision, big complication. Obstet Gynecol (2008) 1.40
Lack of benefit of concurrent chemotherapy in patients with cervical cancer and negative lymph nodes by FDG-PET. Int J Radiat Oncol Biol Phys (2005) 1.39
Frequent HOXA11 and THBS2 promoter methylation, and a methylator phenotype in endometrial adenocarcinoma. Clin Cancer Res (2003) 1.36
Integrative genomics analysis of chromosome 5p gain in cervical cancer reveals target over-expressed genes, including Drosha. Mol Cancer (2008) 1.29
SGO White Paper on ovarian cancer: etiology, screening and surveillance. Gynecol Oncol (2010) 1.27
Fertility preservation in young women with epithelial ovarian cancer. Cancer (2009) 1.24
Quality of perioperative venous thromboembolism prophylaxis in gynecologic surgery. Obstet Gynecol (2011) 1.21
Preoperative lymph node staging of early-stage cervical carcinoma by [18F]-fluoro-2-deoxy-D-glucose-positron emission tomography. Cancer (2005) 1.20
The utility of preoperative endometrial sampling for the detection of uterine sarcomas. Gynecol Oncol (2008) 1.17
Natural history and outcome of mucinous carcinoma of the ovary. Am J Obstet Gynecol (2011) 1.16
Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus cancer. Gynecol Oncol (2004) 1.15
Effect of surgical volume on morbidity and mortality of abdominal hysterectomy for endometrial cancer. Obstet Gynecol (2011) 1.14
Failure to rescue as a source of variation in hospital mortality for ovarian cancer. J Clin Oncol (2012) 1.14
Uterine carcinosarcoma. Curr Opin Oncol (2011) 1.13
Deviations from guideline-based therapy for febrile neutropenia in cancer patients and their effect on outcomes. JAMA Intern Med (2013) 1.13
MSI in endometrial carcinoma: absence of MLH1 promoter methylation is associated with increased familial risk for cancers. Int J Cancer (2002) 1.12
Uterine carcinosarcomas and grade 3 endometrioid cancers: evidence for distinct tumor behavior. Obstet Gynecol (2008) 1.12
The role of radiation in improving survival for early-stage carcinosarcoma and leiomyosarcoma. Am J Obstet Gynecol (2008) 1.12
Occult supraclavicular lymph node metastasis identified by FDG-PET in patients with carcinoma of the uterine cervix. Gynecol Oncol (2003) 1.10
The impact of cervical cancer on quality of life--the components and means for management. Gynecol Oncol (2007) 1.09
Effect of radical cytoreductive surgery on omission and delay of chemotherapy for advanced-stage ovarian cancer. Obstet Gynecol (2012) 1.09
Comparative effectiveness of upfront treatment strategies in elderly women with ovarian cancer. Cancer (2014) 1.08
Peritoneal inclusion cysts: a review. Obstet Gynecol Surv (2009) 1.06
The evolution of cost-effective screening and prevention of cervical carcinoma: implications of the 2006 consensus guidelines and human papillomavirus vaccination. Am J Obstet Gynecol (2007) 1.05
Safety of ovarian preservation in premenopausal women with endometrial cancer. J Clin Oncol (2009) 1.04
Carcinosarcoma of the ovary: natural history, patterns of treatment, and outcome. Gynecol Oncol (2013) 1.03
Pax8: a marker for carcinoma of Müllerian origin in serous effusions. Diagn Cytopathol (2010) 1.03
Use of guideline-based antibiotic prophylaxis in women undergoing gynecologic surgery. Obstet Gynecol (2013) 1.03
Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity: a phase II study of the Gynecologic Oncology Group. J Clin Oncol (2003) 1.03
Patient-reported outcomes in relapsed ovarian cancer: results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD alone. Gynecol Oncol (2012) 1.02
CD83 gene polymorphisms increase susceptibility to human invasive cervical cancer. Cancer Res (2007) 1.01
Feasibility and economic impact of same-day discharge for women who undergo laparoscopic hysterectomy. Am J Obstet Gynecol (2012) 1.01
A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer. Gynecol Oncol (2007) 1.00
Morbidity and mortality of peripartum hysterectomy. Obstet Gynecol (2010) 1.00
Sarcoma of the cervix: natural history and outcomes. Gynecol Oncol (2010) 1.00
The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study. Gynecol Oncol (2009) 1.00
Therapeutic role of lymphadenectomy for cervical cancer. Cancer (2010) 1.00
Patterns of care and treatment outcomes for elderly women with cervical cancer. Cancer (2011) 1.00
Bowel obstruction in elderly ovarian cancer patients: a population-based study. Gynecol Oncol (2012) 0.99
ASTEC lymphadenectomy and radiation therapy studies: are conclusions valid? Gynecol Oncol (2009) 0.98
Clear cell carcinoma of the cervix: a multi-institutional review in the post-DES era. Gynecol Oncol (2008) 0.98
Three cases of hemolytic uremic syndrome in ovarian cancer patients treated with combination gemcitabine and pegylated liposomal doxorubicin. Gynecol Oncol (2005) 0.98
The commercialization of robotic surgery: unsubstantiated marketing of gynecologic surgery by hospitals. Am J Obstet Gynecol (2012) 0.97
Prospective evaluation of positron emission tomography for the detection of groin node metastases from vulvar cancer. Gynecol Oncol (2002) 0.96
The significance of pneumatosis intestinalis or bowel perforation in patients with gynecologic malignancies. Gynecol Oncol (2002) 0.96
Protocadherin PCDH10, involved in tumor progression, is a frequent and early target of promoter hypermethylation in cervical cancer. Genes Chromosomes Cancer (2009) 0.96
Influence of surgical volume on outcome for laparoscopic hysterectomy for endometrial cancer. Ann Surg Oncol (2011) 0.96